Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial

Unknown

(2016)   HIV MEDICINE

Improvement in Insulin Sensitivity and Dyslipidemia in Protease Inhibitor-Treated Adult Male Patients After Switch to Atazanavir/Ritonavir

(2016) Anthony J. Busti et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257

(2015) I. Ofotokun et al.   CLINICAL INFECTIOUS DISEASES

Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks

(2012) Judith A. Aberg et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Defining Insulin Resistance From Hyperinsulinemic-Euglycemic Clamps

(2012) C. S. Tam et al.   DIABETES CARE

Effect of Darunavir on Lipid Profile in HIV-Infected Patients

(2012) Edgar Turner Overton et al.   HIV CLINICAL TRIALS

Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir

(2012) Daria Gotti et al.   HIV CLINICAL TRIALS

Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy

(2010) Robert L Murphy et al.   AIDS

Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men

(2010) Paul A Randell et al.   ANTIVIRAL THERAPY

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

(2010) Jean-Michel Molina et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy

(2009) Regje ME Blümer et al.   AIDS

The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications

(2009) Oliver P. Flint et al.   TOXICOLOGIC PATHOLOGY

Unknown

(2008)   CLINICAL INFECTIOUS DISEASES

Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems

(2008) M. M Kitahata et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Lipoprotein changes in HIV-infected antiretroviral-naïve individuals after starting antiretroviral therapy: ACTG Study A5152s

(2008) James H. Stein et al.   Journal of Clinical Lipidology

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

(2008) Jean-Michel Molina et al.   LANCET

Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage

(2007) Ranganath Muniyappa et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM